Advertisement
Organisation › Details
Riboxx GmbH (Riboxx Pharmaceuticals)
RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer immunotherapy. RIBOXX IP portfolio includes 17 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan. *
Start | 2009-05-01 splitoff | |
Predecessor | Technical University Dresden (TU Dresden) | |
Industry | siRNA technology | |
Industry 2 | Apoxxim® TLR3-ligand | |
Person | Rohayem, Jacques (Riboxx 201602 CEO + CSO) | |
Region | Radebeul | |
Country | Germany | |
Street | 191 Meißner Str. Pharmapark Radebeul | |
City | 01445 Radebeul | |
Tel | +49-351-833601-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2011-12-15) |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top